Unique ID issued by UMIN | UMIN000056780 |
---|---|
Receipt number | R000064901 |
Scientific Title | Exploratory study of the effect on gut microbiota by ingestion of oligosaccharide |
Date of disclosure of the study information | 2025/02/11 |
Last modified on | 2025/01/22 10:40:46 |
Exploratory study of the effect on gut microbiota by ingestion of oligosaccharide
Exploratory study of the effect on gut microbiota by ingestion of oligosaccharide
Exploratory study of the effect on gut microbiota by ingestion of oligosaccharide
Exploratory study of the effect on gut microbiota by ingestion of oligosaccharide
Japan |
Healthy adults
Adult |
Others
NO
To examine the effect on gut microbiota by administration of oligosaccharide for 2 weeks.
Efficacy
Exploratory
Pragmatic
Not applicable
Occupancy rate of each gut microbiota species in feces
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Prevention
Food |
Oral ingestion of oligosaccharide for 2 weeks
Not applicable |
Not applicable |
Male and Female
1. Those who provided specimens in which oligosaccharide increased the number of useful bacteria in vitro
2. Those whose workplace is the Meiji Innovation Center on the date of consent
3. Those who have received sufficient explanation about the purpose and content of this study, have the ability to consent, fully volunteered with voluntary intention, agreed to participate
1. Those who have participated in a study involving another intervention during the month prior to screening or who plan to participate in a study involving another intervention during the period between screening and the end of the intake period
2. Those who have a history of gastric or lower gastrointestinal tract surgery excluding hemorrhoids
3. Those who have a barium stomach X-ray, small or large intestine endoscopy, or bowel cleansing at a clinic or at home during the month prior to screening, or those who are scheduled to have these procedures during this study
4. Who have taken, ingested, or used drugs that may affect the study at least once a week during the month prior to screening, or who plan to take, ingest, or use these drugs at least once during the study
5. Those who plan to travel abroad, travel for more than one week, or go on a business trip during the period from one week prior to the intake period to the end of the intake period
6. Those who have food allergies
7. Those who are pregnant or breastfeeding
8. Subjects judged as unsuitable for the study by the principal investigator or research physician for other reasons
57
1st name | Seiya |
Middle name | |
Last name | Makino |
Meiji Holdings Co., Ltd.
Wellness Science Labs
192-0919
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
042-632-5838
seiya.makino@meiji.com
1st name | Seiya |
Middle name | |
Last name | Makino |
Meiji Holdings Co., Ltd.
Wellness Science Labs
192-0919
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
042-632-5838
seiya.makino@meiji.com
Meiji Holdings Co., Ltd.
Meiji Holdings Co., Ltd.
Profit organization
Meiji Institutional Review Board
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
042-632-5900
MEIJI.IRB@meiji.com
NO
2025 | Year | 02 | Month | 11 | Day |
Unpublished
Preinitiation
2024 | Year | 12 | Month | 17 | Day |
2024 | Year | 12 | Month | 17 | Day |
2025 | Year | 02 | Month | 11 | Day |
2025 | Year | 04 | Month | 30 | Day |
2025 | Year | 01 | Month | 22 | Day |
2025 | Year | 01 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064901